Frederick Munschauer: Treatment of Progressive Multiple Sclerosis Remains a Daunting Task

Even as the number of medications approved to treat relapsing remitting multiple sclerosis continues to grow patients with progressive forms of the condition still await the first approved treatment option to help them.

There has been work done in this area of research and medications, including Ocrelizumab working through the approval process but Frederick Munschauer, MD, from EMD Serono said the process of developing more treatment options is still ongoing. Munschauer discussed the topic during an interview with MD Magazine during the annual meeting of the Consortium of Multiple Sclerosis Centers in National Harbor Maryland.